R&D Projects
8
+
Patents
150
+
Time to IND Filing
Fastest
in
2
years
R&D Investment in 2024
US$25
million
FBDB™
Advantages of Our Technology Platform
Synergistically Re-Activating of Innate and Adaptive Immune Systems Multi targets strategy to eliminate Tumor Cells
Blockade of SIRPα/CD47 Signaling Pathway
Blockade of PD-1/PD-L1 Signaling Pathway
Modulation of the Tumor Microenvironment (TME) to Further Activate Macrophages and T Cells
News
HanchorBio Files U.S. IND for Second Trispecific Immunotherapy, HCB303
HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.
Sep 03, 2026
Read more
HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference
HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
Sep 01, 2026
Read more
HanchorBio Outlines Global Strategy for Gastric Cancer Immunotherapy as HCB101 Advances Beyond Phase 1
HanchorBio announced that Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented the Company’s vision for the next phase of gastric cancer immunotherapy at the Early Phase Clinical Trials: Innovation and Precision Medicine Forum in Taichung, Taiwan.
Aug 24, 2026
Read more
HanchorBio Advances Myeloid-Directed Therapeutics Strategy Beyond Oncology with HCB101 Clinical Progress and FBDB™ Platform Expansion
HanchorBio shared its latest clinical and research progress in myeloid-directed therapeutics at the 2026 Autumn Industry Trends and Corporate Forum hosted by Hua Nan Securities.
The Company presented its development strategy centered on the proprietary FBDB™ multifunctional biologics platform and myeloid enhancer approach, highlighting clinical progress of HCB101 in solid tumors and the expansion of macrophage-directed biology into HCB206 for immune-mediated diseases.
Aug 21, 2026
Read more
HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation
HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.
Aug 20, 2026
Read more
HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
Aug 19, 2026
Read more
HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study
HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study (NCT06771622)
Aug 17, 2026
Read more
HanchorBio Receives FDA Pre-IND Feedback Supporting Advancement of HCB303, a Next-Generation Trispecific Immunotherapy
HanchorBio announced that it has received written responses from the U.S. Food and Drug Administration (FDA) following a Type B pre-Investigational New Drug (pre-IND) submission for HCB303, the Company’s next-generation, first-in-class trispecific immunotherapy designed to simultaneously activate innate and adaptive antitumor immunity.
Aug 12, 2026
Read more
From Macrophage Biology to Clinical Development: HanchorBio Advances the Future of Gastric Cancer Immunotherapy
HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
Aug 10, 2026
Read more
HanchorBio and Taiwan Cancer Moonshot Team Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.
Aug 07, 2026
Read more
JOIN OUR TEAM
